UK–US zero‑tariff deal pricing reforms position UK as global hub for new medicines
The key element of the agreement is confirmation that UK pharmaceutical exports to the US will face a preferential tariff…
Analyst Comment
JPM26: Immunocore Signals Entry into type 1 diabetes
JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens
Transformative arrival of oral weight loss medicines in the US
JPM26: Dealmaking optimism at JPM 2026 despite absence of mega-M&As
JPM26: AbbVie highlights growth drivers as it moves away from Humira dependency
JPM26: Matrix-M Technology is central to Novavax’s strategy
JPM26: Enanta outlines strategy to lead in RSV therapeutics
